Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy

Diabetologia

Volumn 59, Issue 2, 2016, Pages 379-389

  Jha, Jay C ^a,b   Thallas Bonke, Vicki ^a   Banal, Claudine ^a   Gray, Stephen P ^a   Chow, Bryna S M ^a   Ramm, Georg ^c   Quaggin, Susan E ^d   Cooper, Mark E ^a,b   Schmidt, Harald H H W ^e   Jandeleit Dahm, Karin A ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Albuminuria; Diabetic nephropathy; Glomerular basement membrane; NADPH oxidase 4; Podocyte; Reactive oxygen species

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTANE; ALBUMIN; COLLAGEN TYPE 4; FIBRONECTIN; HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PROTEIN KINASE C ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; VASCULOTROPIN; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INACTIVATION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; KIDNEY HYPERTROPHY; KIDNEY STRUCTURE; MALE; METABOLIC PARAMETERS; MOUSE; MOUSE MODEL; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THICKNESS; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL PROTECTION; CHEMICALLY INDUCED; COMPLICATION; EXPERIMENTAL DIABETES MELLITUS; GENE DELETION; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ALBUMINURIA; ANIMALS; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE DELETION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; ORGAN SPECIFICITY; PODOCYTES; STREPTOZOCIN;

EID: 84953353492     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3796-0     Document Type: Article

References (46)

1. Roglic G, Unwin N, Bennett PH et al (2005) The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28:2130–2135
2. Molitch ME, DeFronzo RA, Franz MJ et al (2004) Nephropathy in diabetes. Diabetes Care 27(Suppl 1):S79–s83
3. Bjorn SF, Bangstad HJ, Hanssen KF et al (1995) Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 38:1197–1204
4. Eid AA, Gorin Y, Fagg BM et al (2009) Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 58:1201–1211
5. Tryggvason K, Patrakka J, Wartiovaara J (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354:1387–1401
6. Calcutt NA, Cooper ME, Kern TS, Schmidt AM (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 8:417–429
7. Gill PS, Wilcox CS (2006) NADPH oxidases in the kidney. Antioxid Redox Signal 8:1597–1607
8. Kaneto H, Katakami N, Kawamori D et al (2007) Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 9:355–366
9. Jha JC, Gray SP, Barit D et al (2014) Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25:1237–1254
10. Gorin Y, Block K, Hernandez J et al (2005) Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280:39616–39626
11. Holterman CE, Thibodeau JF, Towaij C et al (2014) Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol 25:784–797
12. Brenner BM, Hostetter TH, Humes HD (1978) Molecular basis of proteinuria of glomerular origin. N Engl J Med 298:826–833
13. Palicz A, Foubert TR, Jesaitis AJ, Marodi L, McPhail LC (2001) Phosphatidic acid and diacylglycerol directly activate NADPH oxidase by interacting with enzyme components. J Biol Chem 276:3090–3097
14. Satoh M, Fujimoto S, Haruna Y et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Ren Physiol 288:F1144–F1152
15. Ding G, Reddy K, Kapasi AA et al (2002) Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Ren Physiol 283:F173–F180
16. Schiffer M, Bitzer M, Roberts IS et al (2001) Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 108:807–816
17. Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54:1626–1634
18. Asaba K, Tojo A, Onozato ML et al (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67:1890–1898
19. Susztak K, Raff AC, Schiffer M, Bottinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233
20. Watson AM, Li J, Schumacher C et al (2010) The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53:192–203
21. Krege JH, Hodgin JB, Hagaman JR, Smithies O (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111–1115
22. Chai Z, Dai A, Tu Y et al (2013) Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. J Am Soc Nephrol 24:1782–1792
23. Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138
24. Mifsud SA, Allen TJ, Bertram JF et al (2001) Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 44:878–882
25. Sato S, Sasaki Y, Adachi A, Ghazizadeh M (2010) Validation of glomerular basement membrane thickness changes with aging in minimal change disease. Pathobiology 77:315–319
26. Koulis C, Chow BS, McKelvey M et al (2015) AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension 65:1073–1081
27. Doublier S, Salvidio G, Lupia E et al (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52:1023–1030
28. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73–80
29. Cooper ME, Mundel P, Boner G (2002) Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 22:393–398
30. Cooper ME, Vranes D, Youssef S et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229–2239
31. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17:3093–3104
32. Thallas-Bonke V, Jha JC, Gray SP et al (2014) Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol Rep 2, e12192
33. Ziyadeh FN, Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4:39–45
34. Zhao QD, Viswanadhapalli S, Williams P et al (2015) NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways. Circulation 131:643–655
35. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37:483–490
36. Tervaert TW, Mooyaart AL, Amann K et al (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21:556–563
37. Mac-Moune Lai F, Szeto CC, Choi PC et al (2004) Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes? Mod Pathol 17:1506–1512
38. Falk RJ, Scheinman JI, Mauer SM, Michael AF (1983) Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 32(Suppl 2):34–39
39. Kim Y, Kleppel MM, Butkowski R, Mauer SM, Wieslander J, Michael AF (1991) Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol 138:413–420
40. Kim J, Shon E, Kim CS, Kim JS (2012) Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res 2012:210821
41. 2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 58:1963–1972
42. Giorgi C, Agnoletto C, Baldini C et al (2010) Redox control of protein kinase C: cell- and disease-specific aspects. Antioxid Redox Signal 13:1051–1085
43. Menne J, Meier M, Park JK et al (2006) Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 70:1456–1462
44. Menne J, Shushakova N, Bartels J et al (2013) Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy. Diabetes 62:1167–1174
45. Quack I, Woznowski M, Potthoff SA et al (2011) PKCα mediates β-arrestin2-dependent nephrin endocytosis in hyperglycemia. J Biol Chem 286:12959–12970
46. Gorin Y, Cavaglieri RC, Khazim K et al (2015) Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Ren Physiol 308:F1276–F1287